Solengepras Meets Phase III Parkinson’s Endpoint

Company Cerevance Event Type Phase 3 topline result (primary endpoint met) Modality Small molecule (oral GPR6 inverse agonist) Asset Solengepras Target GPR6 Disease Area Parkinson’s disease (motor fluctuations) Summary Cerevance reported that once-daily solengepras met the 12-week primary endpoint in Phase III ARISE, reducing daily…